Covered recipient · General Payments record
ANDREA M HERMAN
Allopathic & Osteopathic Physicians Family Medicine
General Payments · PY2018–2024
$1,857.64
- Reported across 113 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $239.99 | 15 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Novo Nordisk AS | $47.90 | 3 |
| Lilly USA, LLC | $41.96 | 3 |
| Bayer HealthCare Pharmaceuticals Inc. | $30.38 | 2 |
| ABBVIE INC. | $28.87 | 2 |
| Seqirus USA Inc | $25.23 | 1 |
| Amgen Inc. | $22.48 | 1 |
| PFIZER INC. | $16.32 | 1 |
| Acerta Pharma LLC | $13.45 | 1 |
| Actelion Pharmaceuticals US, Inc. | $13.40 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (15)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $13.73 | 05/07/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103908594 | CMS |
| ABBVIE INC. | $15.14 | 08/13/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103908596 | CMS |
| Actelion Pharmaceuticals US, Inc. | $13.40 | 08/21/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1078899379 | CMS |
| Amgen Inc. | $22.48 | 02/09/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1111598292 | CMS |
| AstraZeneca Pharmaceuticals LP | $13.45 | 04/10/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105256331 | CMS |
| Bayer Healthcare Pharmaceuticals Inc. | $16.99 | 03/23/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1086177262 | CMS |
| Bayer Healthcare Pharmaceuticals Inc. | $13.39 | 07/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1086195038 | CMS |
| Lilly USA, LLC | $13.24 | 02/08/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135998395 | CMS |
| Lilly USA, LLC | $14.04 | 04/25/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1136032604 | CMS |
| Lilly USA, LLC | $14.68 | 09/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1136035614 | CMS |
| Novo Nordisk Inc | $16.87 | 03/15/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097649355 | CMS |
| Novo Nordisk Inc | $13.53 | 04/26/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1096889646 | CMS |
| Novo Nordisk Inc | $17.50 | 05/22/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1096764199 | CMS |
| PFIZER INC. | $16.32 | 09/25/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131971249 | CMS |
| Seqirus USA Inc | $25.23 | 12/09/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1125630910 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2019, 2020, 2021, 2022, 2023, 2024
- Source files
- Dataset page · Bulk file · PY2018 , PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.